Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Principal Investigator

Erica Warlick, MD, MD

Masonic Cancer Center, University of Minnesota

Intervention

bortezomib(drug)

Enrollment

16 enrolled

Eligibility

18 years · All sexes

Timeline

2009 – 2012

Study locations (1)

• Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Collaborators

Merck Sharp & Dohme LLC · Millennium Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT00658814
  Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
  National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →